Changes in Cerebral Function Parameters in HIV Type 1-Infected Subjects Switching to Darunavir/Ritonavir Either as Monotherapy or with Nucleoside Analogues
Restricted accessLetterFirst published online July, 2011
Changes in Cerebral Function Parameters in HIV Type 1-Infected Subjects Switching to Darunavir/Ritonavir Either as Monotherapy or with Nucleoside Analogues
WilkinTJ, McKinnonJE, DiRienzoAG, MollanK, FletcherCV, MargolisDMet al.Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: Final 48-week clinical and virologic outcomes. J Infect Dis, 2009; 199:866–871.
2.
ArribasJR, DelgadoR, ArranzA, MunozR, PortillaJ, PasquauJet al.Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr, 2009; 51:147–152.
3.
ArribasJR, PulidoF, DelgadoR, LorenzoA, MirallesP, ArranzAet al.Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)J Acquir Immune Defic Syndr, 2005; 40:280–287.
4.
CanestriA, LescureFX, JaureguiberryS, MoulignierA, AmielC, MarcelinAGet al.Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis, 2010; 50:773–778.
5.
GutmannCOM, FuxC. Unexpectedly high failure rate in LPV/r monotherapy arm, involving CNS, and association with low nadir CD4 count in the MOST study. 6th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009.
6.
ArribasJR, HorbanA, GerstoftJ, FatkenheuerG, NelsonM, ClumeckNet al.The MONET trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS, 2010; 24:223–230.
7.
CysiqueLA, MaruffP, DarbyD, BrewBJ. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol, 2006; 21:185–194.
Yilmaz AIA, PriceRW, MallonPW, De MeulderM, TimmermanP, GisslénM. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses, 2009; 25:457–461.
10.
LetendreSRS, BestB. Darunavir concentrations in CSF exceed the median inhibitory concentration. 49th ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy), Francisco, September12–15, 2009.
Kravcik SGK, RothV, CassolS, Hawley-FossN, BadleyAet al.Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acquir Immune Deficiency Syndr, 1991; 21:371–375.
13.
ChangL, ErnstT, WittMD, AmesN, GaiefskyM, MillerE. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients. Neuroimage, 2002; 17:1638–1648.
14.
RossB, BlumlS. Magnetic resonance spectroscopy of the human brain. Anat Rec, 2001; 265:54–84.
15.
PaulRH, YiannoutsosCT, MillerEN, ChangL, MarraCM, SchifittoGet al.Proton MRS and neuropsychological correlates in AIDS dementia complex: Evidence of subcortical specificity. J Neuropsychiat Clin Neurosci, 2007; 19:283–292.
16.
MeyerhoffDJ, BloomerC, CardenasV, NormanD, WeinerMW, FeinG. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV + patients. Neurology, 1999; 52:995–1003.
17.
WinstonA, DuncombeC, LiPC, GillJM, KerrSJ, PulsRet al.Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis, 2010; 50:920–929.
